dr nowzaradan glp 1 drops MassHealth GLP-1 coverage for obesity Friday The GLP-1 Effect: How Weight

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

He runs his clients on a version of Tim Ferrisss 30-30-30 method Read MoreGary Breckas Diet (2026) His Personal Routine & Diet Guidelines

Diabetes is the leading cause of chronic kidney disease

Supports metabolic efficiency and energy balance research

While various medications have been known to cause muscle aches, Glucagon-like peptide 1 (GLP-1) agonists have not been commonly associated with this side effect in medical literature.GLP-1 agonists, such as tirzepatide and semaglutide, are highly effective in promoting weight loss

Individual response varies based on metabolism, genetics, and starting dose